Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Debt (2020 - 2024)

Syndax Pharmaceuticals has reported Non-Current Debt over the past 4 years, most recently at $331.6 million for Q4 2024.

  • Quarterly results put Non-Current Debt at $331.6 million for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $331.6 million (changed N/A YoY), and the annual figure for FY2024 was $331.6 million, changed.
  • Non-Current Debt for Q4 2024 was $331.6 million at Syndax Pharmaceuticals, up from $13.0 million in the prior quarter.
  • Over the last five years, Non-Current Debt for SNDX hit a ceiling of $331.6 million in Q4 2024 and a floor of $11.0 million in Q3 2021.
  • Median Non-Current Debt over the past 4 years was $17.8 million (2020), compared with a mean of $45.3 million.
  • Peak annual rise in Non-Current Debt hit 11.56% in 2021, while the deepest fall reached 45.07% in 2021.
  • Syndax Pharmaceuticals' Non-Current Debt stood at $17.8 million in 2020, then grew by 11.56% to $19.9 million in 2021, then crashed by 34.69% to $13.0 million in 2022, then surged by 2451.68% to $331.6 million in 2024.
  • The last three reported values for Non-Current Debt were $331.6 million (Q4 2024), $13.0 million (Q2 2022), and $16.5 million (Q1 2022) per Business Quant data.